IgG MoDE Degraders: BHV-1300 Phase 1 completing last remaining dose cohorts with the optimized subcutaneous formulation with expected completion in 1H 2025. BHV-1310 first-in-human study anticipated ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

Explore how inhibiting myostatin can promote muscle mass in men, addressing sarcopenia, GLP-1 medication effects, and aging ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and Exchange ...

potentially reducing side effects compared to traditional myostatin inhibitors. Financially, Scholar Rock is well-positioned with a market cap of $4.19bn and a cash runway extending past initial ...

Ibio Inc. has expanded its cardiometabolic and obesity treatment development program by in-licensing a long-acting anti-myostatin antibody from Astralbio Inc. The antibody, now named IBIO-600, was ...

One exciting development among the myostatin inhibitor class, however, is that it has shown signs of being compatible with, and potentially enhancing the effect of, the GLP-1 agonist class of ...